Bioplastics leader Novamont (NB Renaissance-Eni) buys Norway’s BioBag
Together, the two companies will be able to offer the market a more complete range of solutions and create even stronger alliances with key stakeholders, from large retailers to local communities. They will also intensify their joint commitment to innovative projects that improve the separate collection of organic waste and composting systems especially in North America, Scandinavian countries, Eastern Europe and Australia.
Novamont spa, world leader in the production of bioplastics, controlled by NB Renaissance, through Mater-BI spa, and by Versalis (Eni group), announced yesterday the acquisition of BioBag group, a Norwegian company leader in low-impact solutions for the packaging and separate collection of wet waste sectors.
Novamont’s advisors in the transaction were Hi.Lex and Hjort for legal aspects and PWC for financial, tax and labour aspects; for BioBag Bryan Garnier for M&A and Wiersholm for legal aspects.
Read more about BioBag and find the latest economic news with the Born2Invest mobile app.
BioBag International is a leading global group active in the development, production and marketing of certified compostable and biodegradable applications
The group is among the leading producers of environmentally friendly packaging in Northern Europe. In addition to biodegradable and compostable applications, the group offers products based on post-consumer recycled material (PCR) under the GreenPolly brand. With a turnover of $50 million (€41 million) and 135 employees, BioBag is headquartered in Askim in Norway, has a major production site in Estonia, subsidiaries in Sweden, Denmark, Ireland, Finland, Poland, Australia, Canada, USA and representatives in many countries.
The 35% stake in Mater-BI, which controls Novamont at 75%, passed to NB Renaissance in early 2016, along with a group of private equity stakes in other companies all originally held by Intesa Sanpaolo, as part of the spinoff of the bank’s private equity activities conducted in alliance with Neuberger Berman. Intesa Sanpaolo in turn had acquired control of Novamont together with the Investitori Associati II fund in 1996 from the then Montedison group. Investitori Associati II has been in liquidation for years but still appears among the shareholders of Mater-BI with a 35% share, similar to that of Melville srl, a vehicle of NB Renaissance. The rest of Mater-BI’s capital is distributed among various other private and non-private shareholders, including Berger trust.
The Novamont group is a leader in the production of bioplastics and the development of biochemicals and bioproducts through the integration of chemistry, environment, and agriculture. With more than 600 people, it closed 2019 with a turnover of about $329 million (€270 million) and constant investment in research and development (5% compared to turnover, more than 20% of people dedicated). Novamont holds about 1,800 patents and patent applications.
It has headquarters in Novara, production plants in Terni, Bottrighe (RO) and Patrica (FR) and research laboratories in Novara, Terni and Piana di Monte Verna (CE). The company has also established an equal joint venture with Versalis (Eni) in Porto Torres (SS). It is active abroad with offices in Germany, France and the United States and a representative office in Brussels (Belgium). It is present through its own distributors in more than 40 countries on all continents.
In 2020 Novamont obtained the B Corporation certification, thus becoming part of the global B Corp movement, which is rewriting the way of doing business in the world. Aware of how much more can still be done to promote a truly sustainable and inclusive economic model, it has also decided to make its commitment binding, modifying its corporate charter and legally becoming a benefit company.
The acquisition will allow Novamont to benefit from BioBag’s highly specialized independent distribution network in geographic areas where Novamont is less present
Together, the two companies will be able to offer the market a more complete range of solutions and create even stronger alliances with key stakeholders, from large retailers to local communities. They will also intensify their joint commitment to innovative projects that improve the separate collection of organic waste and composting systems, especially in North America, Scandinavian countries, Eastern Europe and Australia.
In the last decade Novamont has been able to expand considerably, particularly through internal growth, acquiring and regenerating obsolete or decommissioned industrial sites. This agreement will allow Novamont to further expand its compostable bioplastics business in Northeast Europe, North America and Australia. BioBag will continue to operate as an independent organization, with the same management team that has performed so well in recent years.
Novamont CEO Catia Bastioli said, “The acquisition of BioBag allows Novamont to expand its circular bioeconomy model. By combining our best skills and energies and fully integrating our supply chains, we can better serve our partners both upstream and downstream in the value chain. The agreement also allows us to further develop circular solutions for different market sectors as well as for communities pursuing our goal of producing more with less.”
BioBag CEO Kjell Ivar Bache added. “We are a very long-standing partner of Novamont and for BioBag it is like coming home. With this transaction, BioBag becomes part of a world-leading bioplastics and biochemicals company and this will enable further growth internationally.”
(Featured image by Volodymyr Hryshchenko via Unsplash)
DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.
This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.
First published in Be Beez, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.
Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.
Vall d’Hebron Invests 50 Million in Projects Against Stroke and Nuclear Medicine
Vall d'Hebron is one of the main public hospitals in Spain. The center received 1.1 million outpatient visits (115,422 more...
Marrakech-Agadir High-Speed Line: ONCF Launches the APS Studies
For ONCF, this line must be designed so that its performance and safety level are globally at least equivalent to...
The TopRanked.io Weekly Digest: What’s Hot in Affiliate Marketing [Week 13]
When in doubt, we at TopRanked prefer optimism. But when it's week 13 and the world's screaming AI FUD, maybe...
Pampa Hemp Introduces First Medical Cannabis Seed Developed and Produced in Argentina
Argentina has been developing its cannabis production chain in recent years, promoting medical and scientific research on the medicinal use...
Paraguayan Chamber of Fintech Supports Controls on Illegal Crypto Mining
By the end of 2022, a special price was defined for the intensive consumption group. In that set, they included...
Featured1 week ago
Fintech Company Raisin Receives Unicorn Status After New Financial Injection
Biotech4 days ago
Moderna Will Pay $70 Million to Generation Bio for Genetic Medicines
Featured2 weeks ago
Corn Closed Higher Last Week and Short-Term Trends Are Up
Biotech2 days ago
Vytrus Biotech Increases Sales by 31% and Achieves an EBITDA of €1.5 Million